Comparison of BNP and NT-proBNP assays in the approach to the emergency diagnosis of acute dyspnea

Journal of Clinical Laboratory Analysis

Volumn 20, Issue 6, 2006, Pages 227-232

  Sanz, M P ^a   Borque De Larrea, Luis ^a   Rus, A ^a   Vicente, B ^a   Ramirez Y ^a   Lasa, L ^a  

^a HOSPITAL SAN PEDRO   (Spain)

Author keywords

Brain natriuretic peptides; Dyspnea; Heart failure; Respiratory disease method comparison

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL ACTIVE COOH TERMINAL PEPTIDE; BRAIN NATRIURETIC PEPTIDE; PEPTIDE;

ADULT; AGED; ARTICLE; CAUSAL ATTRIBUTION; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DYSPNEA; EMERGENCY CARE; FEMALE; HEART DISEASE; HUMAN; INTERMETHOD COMPARISON; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; QUANTITATIVE DIAGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STANDARDIZATION;

AGED; BLOOD CHEMICAL ANALYSIS; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; DYSPNEA; EMERGENCY MEDICAL SERVICES; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; RESPIRATORY TRACT DISEASES; SENSITIVITY AND SPECIFICITY;

EID: 33845260128     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20146     Document Type: Article

References (21)

1. McCullough PA, Omland T, Maisel AS. B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Rev Cardiovasc Med 2003;4:72-80.
2. Mair J, Hammerer A, Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001;39:571-588.
3. Mair J, Friedl W, Thomas S, Puschendorf B. Natriuretic peptides in assessment of left-ventricular dysfunction. Scand J Clin Lab Invest 1999;59:132-142.
4. Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail 2004;6:257-260.
5. Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides. Clin Chem 2004;50:2465-2468.
6. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart in primary care. Lancet 1997;350:1349-1353.
7. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13.
8. Darbar D, Davidson NC, Gillespie N, et al. Diagnostic value of B-type natriuretic peptide concentrations in patients with acute myocardial infarction. Am J Cardiol 1996;78:284-287.
9. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-1130.
10. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-1560.
11. McCullough, PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure analysis from breathing not properly (BNP) multinational study. Circulation 2002;106:416-422.
12. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004;350:647-654.
13. Davies MK, Hobbs FDR, Davis RC, et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet 2001;358:439-444.
14. Prontera C, Emdin M, Zucchelli GC, Ripoli A, Passino C, Clerico A. Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide. Clin Chem Lab Med 2004;42:37-44.
15. Rawlins ML, Owen WE, Roberts WL. performance characteristics of four automated natriuretic peptide assays. Am J Clin Pathol 2005;123:439-445.
16. Yeo KTJ, Wu AHB, Apple FS, et al. Muticenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 2003;338:107-115.
17. Wu AHB, Packer M, Smith A, et al. Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study. Clin Chem 2004;50:867-873.
18. Cook DG, Shaper AG. Breathlessness, lung function and the risk of heart attack. Eur Heart J 1988;9:1215-1222.
19. Vanderheyden M, Bartunek J, Goethals M. Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail 2004;6:261-268.
20. Ala-Kopsal M, Magga J, Peuhkurinen K. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A-and B-type natriuretic peptides. Clin Chem 2004;50:1576-1588.
21. Cowie MR. B-type natriuretic peptide testing: where are we now?. Heart 2004;90:725-726.